The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin)

Journal of Neuro-Oncology

Volumn 34, Issue 2, 1997, Pages 145-151

  Kaba, Samer E ^a,b   Kyritsis, Athanassios P ^a   Conrad, Charles ^a   Gleason, Mary Jo ^a   Newman, Robert ^a   Levin, Victor A ^a   Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

All trans retinoic acid; Brain neoplasm; Malignant glioma; Retinoids

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BRAIN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; NAUSEA; NEUROBLASTOMA CELL; OLIGODENDROGLIOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SCHOOL CHILD; SKIN DISEASE; TUMOR GROWTH; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HEADACHE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN; TIME FACTORS; TRETINOIN;

EID: 0031008860     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005743707803     Document Type: Article

References (32)

1. Kornblith PL, Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1-17, 1992
2. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Norrell HA, Owens G, Ransohoff J II, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333-343, 1992
3. Levin VA, Silver P, Hannigan J, Wara WM, Gutin P, Davis RL, Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 Final Report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990
4. Jeremic B, Jovanovic D, Djuric LJ, Jeveremovic S, Mijatovic LJ: Advantage of post radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J Chemotherapy 4: 123-126, 1992
5. Yung WKA: Chemotherapy for malignant brain tumors. Curr Opin Oncol 2: 673-678, 1990
6. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992
7. Sporn MB, Roberts AB, Roche NS, Kagechika H, Shudo K: Mechanism of action of retinoids. J Am Acad Dermatol 15: 756-764, 1986
8. Rodts GE Jr, Black KL: Trans retinoic acid inhibits in vivo tumor growth of C6 glioma in rats: effect negatively influenced by nerve growth factor. Neurol Res 16: 184-186
9. Yung WKA, Lotan D, Lee R, Steck PA: Modulation of growth and EGF receptor activity by retinoic acid in human glioma cells. Cancer Res 1989 49: 1014-1019, 1994
10. Melino G, Stephanou A, Annicchiarico-Petruzzelli M, Knight RA, Finazzi-Agr'o A, Lightman SL: Modulation of IGF-2 expression during growth and differentiation of human neuroblastoma cells: Retinoic acid may induce IGF-2. Neurosci Lett 151: 187-191, 1993
11. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, Lanotte M, Berger R, Chambon P: Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins. EMBO J 11: 629-642, 1992
12. Alcalay M, Zangrilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, Rocchi M, Biondi A, Rambaldi A, Lo Coco F, Diverio D, Donti E, Grignani F, Pelicci PG: Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor α locus. Proc Natl Acad Sci 88: 1991
13. Dennert G, Crowley C, Kouba J, Lotan R: Retinoid acid stimulation of the induction of mouse killer T-cells in allogenic and syngeneic systems. J Natl Cancer Inst 62: 89-94, 1979
14. Dennert G, Lotan R: Effect of retinoic acid on the immune system: Stimulation of T-killer cell induction. Eur J Immunol 8: 23-29, 1978
15. Rotello R, Lieberman R, Purchio A: Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells. Proc Natl Acad Sci 88: 3412-3415, 1991
16. Claxton DF, Plunkett W Jr, Andreeff M, Deisseroth A: Retinoids and Cancer Therapy. J Natl Cancer Inst 84: 1306-1307, 1992
17. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S, Degos L: Retinoic acid therapy for promyelocytic leukemia. Lancet 2: 746-747, 1989
18. Castaigne S, Chomienne C, Daniel MT, Bellarini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 76: 1704-1709, 1990
19. Wang CJ, Chou MY, Lin JK: Inhibition of growth and development of the transplantable C-6 glioma cells inoculated in rats by retinoids and carotenoids. Cancer Lett 48: 135-142, 1989
20. Fischer I, Nolan C, Shea T: Effects of retinoic acid on expression of transformed phenotype in C6 glioma cells. Life Sciences 41: 463-470, 1987
21. Preis PN, Saya H, Nadashi L, Hochaus G, Levin V, Sad'ee W: Neuronal cell differentiation of human neuroblastoma cells by retinoic acid plus herbimycin-a. Cancer Res 48: 6530-6534, 1988
22. Rodriguez LA, Prados M, Silver P, Levin V: Re-evaluation of procarbazine for the treatment of recurrent malignant CNS tumors. Cancer 64: 2420-2425, 1989
23. Wilson CB, Gutin P, Boldrey EB: Single-agent chemotherapy of brain tumors. Arch Neurol 33: 709-714, 1976
24. Yung WKA, Mechtler L, Gleason MJ: Intravenous Carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol 9: 860-864, 1991
25. Yung WKA, Prados M, Levin VA, Fetell MR, Bennet J, Mahaley MS, Scalman M, Ectubanas E: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study. J Clin Oncol 9: 1945-1949, 1991
26. Gallagher RE, Said F, Pua I, Papenhausen PR, Paietta E, Wiernik PH: Expression of retinoic acid receptor-α mRNA in human leukemia cells with variable responsiveness to retinoic acid. Leukemia 3: 789-795, 1989
27. Hu L, Crowe D, Rheinwald J, Chambon P, Gudas LJ: Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 51: 3972-3981, 1991
28. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD, Fenton RM: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10: 1666-1673, 1992
29. Adamson PC: Pharmacokinetics of all-trans-retinoic acid: Clinical implications in acute promyelocytic leukemia. Semin Hematol 31: 14-17, 1994
30. Muindi JR, Young CW, Warrell RP Jr: Clinical pharmacology of all-trans retinoic acid. Leukemia 8 Suppl 3: S16-21, 1994
31. Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, Krakoff IH, Hong WK: Phase I evaluation of All-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 31: 1501-1508, 1995
32. Miller VA, Rigas JR, Muindi JR, Tong WP, Venkatraman E, Kris MG, Warrell RP Jr: Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemo Pharm 34: 522-526, 1994